Drug Profile

Alcohol-use disorder and depression therapeutic - Lohocla Research

Alternative Names: Nezavist

Latest Information Update: 20 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lohocla Research
Class Antidepressants; Drug withdrawal therapies
Mechanism of Action GABA receptor agonists; Glutamate antagonists; NMDA receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

20 Jan 2025 Nezavist is still in preclinical development in Alcoholism in USA, preclinical development in Depressive disorders in USA (Lohocla Research pipeline, January 2025)
20 Jan 2025 Lohocla Research has received clearance from the FDA to begin first-in-human trials (Lohocla Research pipeline, January 2025)
09 Oct 2024 Lohocla Research Corporation plans a phase I trial (In volunteers) in USA (PO) in January 2025 (NCT06633562)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com